Inozyme Pharma (Inozyme Pharma) Days Inventory : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Inozyme Pharma's Average Total Inventories for the three months ended in Mar. 2024 was $0.00 Mil. Inozyme Pharma's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Inozyme Pharma's Days Inventory or its related term are showing as below:

INZY's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 193.29
* Ranked among companies with meaningful Days Inventory only.

Inozyme Pharma's Days Inventory stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Inozyme Pharma Days Inventory Historical Data

The historical data trend for Inozyme Pharma's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma Days Inventory Chart

Inozyme Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Inozyme Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inozyme Pharma's Days Inventory

For the Biotechnology subindustry, Inozyme Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inozyme Pharma's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Days Inventory distribution charts can be found below:

* The bar in red indicates where Inozyme Pharma's Days Inventory falls into.

Inozyme Pharma Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inozyme Pharma's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Inozyme Pharma's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:

	Days Inventory (Q: Mar. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Inozyme Pharma (NAS:INZY) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Inozyme Pharma's Inventory Turnover for the three months ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Inozyme Pharma's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Inozyme Pharma Days Inventory Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Inozyme Pharma (Inozyme Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Summer Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.inozyme.com

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Executives

Robert Lorne Hopfner	director, 10 percent owner	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton	officer: COO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian	officer: SVP, CFO	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke	officer: See Remarks	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte	director, 10 percent owner, officer: See Remarks	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc.	director	321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert	officer: SVP, CMO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025